BioMarin Pharmaceutical Inc. Profile and SWOT Analysis Report 2018

Report Name: BioMarin Pharmaceutical Inc. Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation

BioMarin Pharmaceutical Inc. Report – Publisher: Research Cosmos

Price Scheme of the Report:

Single User License – USD 150

Team License – USD 175

Corporate License – USD 250

BioMarin Pharmaceutical Inc.  – Business Description:

BioMarin Pharmaceutical Inc. is engaged in the development and commercialization of biopharmaceuticals. The company has its operations in the US, Europe, Latin America, and other regions of the world.

The company operates in one business segment focused on the development and commercialization of innovative therapies for people with serious and life threatening rare diseases and medical conditions.

The company’s product portfolio consists of five approved products and multiple clinical and pre-clinical product candidates. Approved products of the company are Naglazyme (galsulfase); Kuvan (sapropterin dihydrochloride); Aldurazyme (laronidase); Vimizim; and Firdapse.

Naglazyme, a product developed and commercialized by BioMarin, is indicated for the treatment of mucopolysaccharidosis VI (MPS VI). In FY2016, Naglazyme reported revenues of $296.5 million, which accounted for 26.5% of the company’s total revenue.

Kuvan, indicated for phenylketonuria (PKU), is manufactured and commercialized by BioMarin globally (except in Japan). In FY2016, Kuvan reported revenues of $348 million, which accounted for 31.2% of the company’s total revenue.

Aldurazyme, for the treatment of mucopolysaccharidosis I (MPS I), is a product which BioMarin developed through a 50:50 joint venture with Genzyme. In FY2016, Aldurazyme reported revenues of $93.8 million, which accounted for 8.4% of the company’s total revenue.

Vimizim is an enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis IV Type A (MPS IVA). In FY2016, Vimizim reported revenues of $354.1 million, which accounted for 31.7% of the company’s total revenue.

Firdapse, approved by the European Commission, is indicated for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). In FY2016, Firdapse reported revenues of $18 million, which accounted for 1.6% of the company’s total revenue.

BioMarin also generates revenues from royalty and other sources. In FY2016, royalty and other revenues of BioMarin were $6.5 million, which accounted for 0.6% of the company’s total revenue.

Product candidates of BioMarin include Brineura (formerly referred to as cerliponase alfa or BMN 190) for the treatment of late infantile neuronal ceroid lipofuscinosis (CLN2), a form of Batten disease; pegvaliase (formerly referred to as PEG PAL), an enzyme substitution therapy for the treatment of PKU; and vosoritide (formerly referred to as BMN 111), a peptide therapeutic for the treatment of achondroplasia, the leading cause of dwarfism.

Other product candidates of the company include BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase (NAGLU) with a peptide derived from insulin-like growth factor 2 (IGF2), for the treatment of Sanfilippo B syndrome, or Mucopolysaccharidosis type IIIB (MPS IIIB). BioMarin is conducting or planning to conduct preclinical development of several other product candidates for genetic and other metabolic diseases.

Geographically, the company classifies its operations into four segments, namely the US, Europe, Latin America, and Rest of World. In FY2016, the US segment accounted for 45.4% of the company’s total revenues, followed by Europe with 22.6%; Latin America with 13.3%; and Rest of World with 18.7%.

Scope of the Report:

About the Company: Historical Details, Current Ownership Structure and basic overview of Balfour Beatty plcin terms of revenue, net income, and operating income.

Financials: Details about Balfour Beatty plclisting status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.

Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.

Company SWOT Analysis: Outlines Atea ASA.’s strengths, weaknesses, and opportunities and threats facing the company.

Recent Developments: Showcases Atea ASA.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.

Strategic Evaluation: This section provides an overview of Atea ASA.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.

Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.

Key Questions Answered

What domain does Balfour Beatty plcoperate and what are key points about it?

What is the product/service portfolio of Atea ASA.?

How has Balfour Beatty plcperformed financially from 2013?

How does Balfour Beatty plcrank among its peers in terms of revenue and market share?

What are Balfour Beatty plcstrengths and weaknesses and what opportunities and threats do it face?

What are Atea ASA.’s main growth strategies and how successful has the company been at implementing them?

What is the in-house technical capability of Atea ASA.? Where does it procure/outsource it?

Reasons to buy

Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own

Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost

12 hour delivery time fulfilling your urgent requests as per your requirement

On-demand customization options that can completely cater to your needs by focusing the report on given specifics

For More Information, Get Sample of the report:Request Sample

Got Some Questions? Inquire Here:Inquire Before Buying

Get This Report:Purchase Now

For More Details, Contact Provider Directly:

Kevin Stewart
Sales Manager
Research Cosmos
+1 888 709 8757

Be the first to comment

Leave a Reply